Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients

Table 2

Patients’ characteristics during ACT.

Patient	Sex	Age	PS	LDH level	AJCC stage	Biopsy site used for TIL extraction	Size of excised tumor (cm^3)	TIL infusion		TIL amount injected (10^9)	Metastases	Response	Adverse events		PFS (months)	OS (months)
								Year	n				Grade 1-2	Grade 3
1	F	17	0	2 N	IV	SCnod	6	2009	2	8.9	Skin, liver, lung, adrenal, small intestine	PD	Asthenia, anorexia, thrombocytopenia			12.9
2	F	37	0	1.5 N	IV	SCnod	1	2009	4	13.35	Skin, LN, lung	PR then PD	Asthenia, myalgias	Nausea, vomiting		110^a
3	F	71	0	2 N	IV	SCnod	3	2009	2	9.0	Skin	PD			3.0	5.7
4	F	64	0	N	IIIC	Cnod	147	2010	2	1.87	Skin	CR				100
5	F	41	0	N	IV	SCnod	5	2010	2	0.23	SC, lung, liver, colon	PD	Asthenia, myalgia, nausea		3.3	100^a
6	F	76	0	1.5 N	IV	Cnod	36	2011	2	4.70	Skin	PD			2.0	14.8
7	F	72	1	N	IV	Cnod	6	2011	2	22.90	Skin, LN, bone	PD	Anorexia, rash		3.0	12.3
8	M	88	2	1.5 N	IIIC	Cnod	2	2012	2	4.20	Skin	SD	Ageusia, asthenia, pruritus			31.8
9	F	83	1	N	IIIC	Cnod	140	2012	2	3.10	Skin, LN	PD	Asthenia, flu-like syndrome		4.9	8.4
10	F	73	0	N	IIIC	Cnod	0.75	2012	2	3	Skin	SD then PD	Anorexia, asthenia, flu-like syndrome		7.9	45.0

AJCC: American Joint Committee on Cancer; Cnod: cutaneous nodule; CR: complete response; Skin: cutaneous; N: normal range; PD: progressive disease; PFS: progression-free survival; PR: partial response; PS: performance status; SD: stable disease; SC: subcutaneous; SCnod: subcutaneous nodule. ^aOngoing.